drugset

drugset / Trial / NCT01934166

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

NCT01934166 ↗

Phase 1 Completed 32 enrolled H. Lundbeck A/S

NaSingle-groupOpen-label

Summary

To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene

Timeline

Start: 2013-07
Primary completion: 2014-08
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nalmefene	Small molecule	18 mg	Oral

Indications